KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Cash from Investing Activities (2020 - 2025)

Historic Cash from Investing Activities for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $36.5 million.

  • AbCellera Biologics' Cash from Investing Activities rose 88669.55% to $36.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.3 million, marking a year-over-year decrease of 2128.93%. This contributed to the annual value of $121.4 million for FY2024, which is 15490.94% up from last year.
  • Latest data reveals that AbCellera Biologics reported Cash from Investing Activities of $36.5 million as of Q3 2025, which was up 88669.55% from -$31.8 million recorded in Q2 2025.
  • AbCellera Biologics' 5-year Cash from Investing Activities high stood at $52.1 million for Q2 2024, and its period low was -$282.0 million during Q3 2022.
  • For the 5-year period, AbCellera Biologics' Cash from Investing Activities averaged around -$40.6 million, with its median value being -$17.1 million (2022).
  • In the last 5 years, AbCellera Biologics' Cash from Investing Activities crashed by 684018.02% in 2021 and then soared by 88669.55% in 2025.
  • AbCellera Biologics' Cash from Investing Activities (Quarter) stood at -$1.1 million in 2021, then tumbled by 1385.03% to -$17.1 million in 2022, then plummeted by 42.55% to -$24.3 million in 2023, then surged by 246.79% to $35.7 million in 2024, then grew by 2.2% to $36.5 million in 2025.
  • Its Cash from Investing Activities stands at $36.5 million for Q3 2025, versus -$31.8 million for Q2 2025 and $7.9 million for Q1 2025.